Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Aug;16(8):e010700.
doi: 10.1161/CIRCHEARTFAILURE.123.010700. Epub 2023 Jun 8.

Imaging and Serum Biomarkers for Cardiomyopathy in Duchenne Muscular Dystrophy

Elizabeth M McNally  1 , Karisma R Chhabria  1 , Dominic E Fullenkamp  1
Affiliations
Editorial

Imaging and Serum Biomarkers for Cardiomyopathy in Duchenne Muscular Dystrophy

Elizabeth M McNally et al. Circ Heart Fail. 2023 Aug.
No abstract available

Keywords: BNP; Editorials; dystrophin; exon; heart failure; magnetic resonance imaging; mutation.

PubMed Disclaimer

Conflict of interest statement

Disclosures Dr McNally is or has been a consultant for Amgen, AstraZeneca, Avidity Biosciences, Cytokinetics, Pfizer, PepGen, and Tenaya Therapeutics and is the founder of Ikaika Therapeutics. The other authors report no conflicts.

Comment on

References

    1. Gloss D RTM III, Ashwal S, Oskoui M. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy. Report of the Guideline Development Subcommittee of the American Academy of Neurology. 2016;86:465–472. doi: 10.1212/wnl.0000000000002337 - DOI - PMC - PubMed
    1. Moxley RT 3rd, Pandya S, Ciafaloni E, Fox DJ, Campbell K. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol. 2010;25:1116–1129. doi: 10.1177/0883073810371004 - DOI - PubMed
    1. Buddhe S, Cripe L, Friedland-Little J, Kertesz N, Eghtesady P, Finder J, Hor K, Judge DP, Kinnett K, McNally EM, et al. Cardiac Management of the Patient With Duchenne Muscular Dystrophy. Pediatrics. 2018;142:S72–s81. doi: 10.1542/peds.2018-0333I - DOI - PMC - PubMed
    1. Porcher R, Desguerre I, Amthor H, Chabrol B, Audic F, Rivier F, Isapof A, Tiffreau V, Campana-Salort E, Leturcq F, et al. Association between prophylactic angiotensin-converting enzyme inhibitors and overall survival in Duchenne muscular dystrophy-analysis of registry data. Eur Heart J. 2021;42:1976–1984. doi: 10.1093/eurheartj/ehab054 - DOI - PubMed
    1. Filonova G, Aartsma-Rus A. Next steps for the optimization of exon therapy for Duchenne muscular dystrophy. Expert Opin Biol Ther. 2023;23:133–143. doi: 10.1080/14712598.2023.2169070 - DOI - PubMed

MeSH terms